Type 1 diabetes, COVID-19 vaccines and short-term safety : Subgroup analysis from the global COVAD study
© 2023 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd..
AIMS/INTRODUCTION: Coronavirus disease 2019 (COVID-19) vaccinations have been proven to be generally safe in healthy populations. However, the data on vaccine safety in patients with type 1 diabetes are scarce. This study aimed to evaluate the frequency and severity of short-term (<7-day) adverse vaccination events (AEs) and their risk factors among type 1 diabetes patients.
MATERIALS AND METHODS: This study analyzed data from the COVID-19 vaccination in Autoimmune Diseases (COVAD) survey database (May to December 2021; 110 collaborators, 94 countries), comparing <7-day COVID-19 vaccine AE among type 1 diabetes patients and healthy controls (HCs). Descriptive statistics; propensity score matching (1:4) using the variables age, sex and ethnicity; and multivariate analyses were carried out.
RESULTS: This study analyzed 5,480 completed survey responses. Of all responses, 5,408 were HCs, 72 were type 1 diabetes patients (43 females, 48.0% white European ancestry) and Pfizer was the most administered vaccine (39%). A total of 4,052 (73.9%) respondents had received two vaccine doses. Patients with type 1 diabetes had a comparable risk of injection site pain, minor and major vaccine AEs, as well as associated hospitalizations to HCs. However, type 1 diabetes patients had a higher risk of severe rashes (3% vs 0.4%, OR 8.0, 95% confidence interval 1.7-36), P = 0.007), although reassuringly, these were rare (n = 2 among type 1 diabetes patients).
CONCLUSIONS: COVID-19 vaccination was safe and well tolerated in patients with type 1 diabetes with similar AE profiles compared with HCs, although severe rashes were more common in type 1 diabetes patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Journal of diabetes investigation - 15(2024), 1 vom: 01. Jan., Seite 131-138 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chatterjee, Tulika [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 03.01.2024 Date Revised 04.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jdi.14079 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361952236 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361952236 | ||
| 003 | DE-627 | ||
| 005 | 20240108141623.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jdi.14079 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1248.xml |
| 035 | |a (DE-627)NLM361952236 | ||
| 035 | |a (NLM)37697820 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chatterjee, Tulika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Type 1 diabetes, COVID-19 vaccines and short-term safety |b Subgroup analysis from the global COVAD study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2024 | ||
| 500 | |a Date Revised 04.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. | ||
| 520 | |a AIMS/INTRODUCTION: Coronavirus disease 2019 (COVID-19) vaccinations have been proven to be generally safe in healthy populations. However, the data on vaccine safety in patients with type 1 diabetes are scarce. This study aimed to evaluate the frequency and severity of short-term (<7-day) adverse vaccination events (AEs) and their risk factors among type 1 diabetes patients | ||
| 520 | |a MATERIALS AND METHODS: This study analyzed data from the COVID-19 vaccination in Autoimmune Diseases (COVAD) survey database (May to December 2021; 110 collaborators, 94 countries), comparing <7-day COVID-19 vaccine AE among type 1 diabetes patients and healthy controls (HCs). Descriptive statistics; propensity score matching (1:4) using the variables age, sex and ethnicity; and multivariate analyses were carried out | ||
| 520 | |a RESULTS: This study analyzed 5,480 completed survey responses. Of all responses, 5,408 were HCs, 72 were type 1 diabetes patients (43 females, 48.0% white European ancestry) and Pfizer was the most administered vaccine (39%). A total of 4,052 (73.9%) respondents had received two vaccine doses. Patients with type 1 diabetes had a comparable risk of injection site pain, minor and major vaccine AEs, as well as associated hospitalizations to HCs. However, type 1 diabetes patients had a higher risk of severe rashes (3% vs 0.4%, OR 8.0, 95% confidence interval 1.7-36), P = 0.007), although reassuringly, these were rare (n = 2 among type 1 diabetes patients) | ||
| 520 | |a CONCLUSIONS: COVID-19 vaccination was safe and well tolerated in patients with type 1 diabetes with similar AE profiles compared with HCs, although severe rashes were more common in type 1 diabetes patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Type 1 diabetes mellitus | |
| 650 | 4 | |a Vaccine | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Ravichandran, Naveen |e verfasserin |4 aut | |
| 700 | 1 | |a Nair, Narmadha |e verfasserin |4 aut | |
| 700 | 1 | |a Gracia-Ramos, Abraham Edgar |e verfasserin |4 aut | |
| 700 | 1 | |a Barman, Bhupen |e verfasserin |4 aut | |
| 700 | 1 | |a Sen, Parikshit |e verfasserin |4 aut | |
| 700 | 1 | |a Joshi, Mrudula |e verfasserin |4 aut | |
| 700 | 1 | |a Saha, Sreoshy |e verfasserin |4 aut | |
| 700 | 1 | |a Nune, Arvind |e verfasserin |4 aut | |
| 700 | 1 | |a Pande, Arun Kumar R |e verfasserin |4 aut | |
| 700 | 1 | |a Velikova, Tsvetelina |e verfasserin |4 aut | |
| 700 | 1 | |a Parodis, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Ai Lyn |e verfasserin |4 aut | |
| 700 | 1 | |a Shinjo, Samuel Katsuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Boro, Hiya |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Vikas |e verfasserin |4 aut | |
| 700 | 1 | |a Aggarwal, Rohit |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Latika |e verfasserin |4 aut | |
| 700 | 0 | |a COVAD Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Nikiphorou, Elena |e investigator |4 oth | |
| 700 | 1 | |a Lilleker, James B |e investigator |4 oth | |
| 700 | 1 | |a Chinoy, Hector |e investigator |4 oth | |
| 700 | 1 | |a Day, Jessica |e investigator |4 oth | |
| 700 | 1 | |a Ziade, Nelly |e investigator |4 oth | |
| 700 | 1 | |a Salim, Babur |e investigator |4 oth | |
| 700 | 1 | |a Saavedra, Miguel A |e investigator |4 oth | |
| 700 | 1 | |a Cavagna, Lorenzo |e investigator |4 oth | |
| 700 | 1 | |a Milchert, Marcin |e investigator |4 oth | |
| 700 | 1 | |a Knitza, Johannes |e investigator |4 oth | |
| 700 | 1 | |a Kuwana, Masataka |e investigator |4 oth | |
| 700 | 1 | |a Distler, Oliver |e investigator |4 oth | |
| 700 | 1 | |a Kardes, Sinan |e investigator |4 oth | |
| 700 | 1 | |a Kim, Minchul |e investigator |4 oth | |
| 700 | 1 | |a Gheita, Tamer A |e investigator |4 oth | |
| 700 | 1 | |a Singh, Yogesh Preet |e investigator |4 oth | |
| 700 | 1 | |a Ranjan, Rajiv |e investigator |4 oth | |
| 700 | 1 | |a Jain, Avinash |e investigator |4 oth | |
| 700 | 1 | |a Pandya, Sapan C |e investigator |4 oth | |
| 700 | 1 | |a Pilania, Rakesh Kumar |e investigator |4 oth | |
| 700 | 1 | |a Sharma, Aman |e investigator |4 oth | |
| 700 | 1 | |a Manoj M, Manesh |e investigator |4 oth | |
| 700 | 1 | |a Gupta, Vikas |e investigator |4 oth | |
| 700 | 1 | |a Kavadichanda, Chengappa G |e investigator |4 oth | |
| 700 | 1 | |a Patro, Pradeepta Sekhar |e investigator |4 oth | |
| 700 | 1 | |a Ajmani, Sajal |e investigator |4 oth | |
| 700 | 1 | |a Phatak, Sanat |e investigator |4 oth | |
| 700 | 1 | |a Goswami, Rudra Prosad |e investigator |4 oth | |
| 700 | 1 | |a Chowdhury, Abhra Chandra |e investigator |4 oth | |
| 700 | 1 | |a Mathew, Ashish Jacob |e investigator |4 oth | |
| 700 | 1 | |a Shenoy, Padnamabha |e investigator |4 oth | |
| 700 | 1 | |a Asranna, Ajay |e investigator |4 oth | |
| 700 | 1 | |a Bommakanti, Keerthi Talari |e investigator |4 oth | |
| 700 | 1 | |a Shukla, Anuj |e investigator |4 oth | |
| 700 | 1 | |a Chandwar, Kunal |e investigator |4 oth | |
| 700 | 1 | |a Agarwal, Vishwesh |e investigator |4 oth | |
| 700 | 1 | |a Jagtap, Kshitij |e investigator |4 oth | |
| 700 | 1 | |a Cansu, Döndü Üsküdar |e investigator |4 oth | |
| 700 | 1 | |a Pauling, John D |e investigator |4 oth | |
| 700 | 1 | |a Wincup, Chris |e investigator |4 oth | |
| 700 | 1 | |a Makol, Ashima |e investigator |4 oth | |
| 700 | 1 | |a Del Papa, Nicoletta |e investigator |4 oth | |
| 700 | 1 | |a Sambataro, Gianluca |e investigator |4 oth | |
| 700 | 1 | |a Fabiola, Atzeni |e investigator |4 oth | |
| 700 | 1 | |a Govoni, Marcello |e investigator |4 oth | |
| 700 | 1 | |a Parisi, Simone |e investigator |4 oth | |
| 700 | 1 | |a Bocci, Elena Bartoloni |e investigator |4 oth | |
| 700 | 1 | |a Sebastiani, Gian Domenico |e investigator |4 oth | |
| 700 | 1 | |a Fusaro, Enrico |e investigator |4 oth | |
| 700 | 1 | |a Sebastiani, Marco |e investigator |4 oth | |
| 700 | 1 | |a Quartuccio, Luca |e investigator |4 oth | |
| 700 | 1 | |a Franceschini, Franco |e investigator |4 oth | |
| 700 | 1 | |a Sainaghi, Pier Paolo |e investigator |4 oth | |
| 700 | 1 | |a Orsolini, Giovanni |e investigator |4 oth | |
| 700 | 1 | |a De Angelis, Rossella |e investigator |4 oth | |
| 700 | 1 | |a Danielli, Maria Giovanna |e investigator |4 oth | |
| 700 | 1 | |a Venerito, Vincenzo |e investigator |4 oth | |
| 700 | 1 | |a Traboco, Lisa S |e investigator |4 oth | |
| 700 | 1 | |a Wibowo, Suryo Anggoro Kusumo |e investigator |4 oth | |
| 700 | 1 | |a Serrano, Jorge Rojas |e investigator |4 oth | |
| 700 | 1 | |a García-De La Torre, Ignacio |e investigator |4 oth | |
| 700 | 1 | |a Tehozol, Erick Adrian Zamora |e investigator |4 oth | |
| 700 | 1 | |a Loarce-Martos, Jesús |e investigator |4 oth | |
| 700 | 1 | |a Prieto-González, Sergio |e investigator |4 oth | |
| 700 | 1 | |a Gonzalez, Raquel Aranega |e investigator |4 oth | |
| 700 | 1 | |a Yoshida, Akira |e investigator |4 oth | |
| 700 | 1 | |a Nakashima, Ran |e investigator |4 oth | |
| 700 | 1 | |a Sato, Shinji |e investigator |4 oth | |
| 700 | 1 | |a Kimura, Naoki |e investigator |4 oth | |
| 700 | 1 | |a Kaneko, Yuko |e investigator |4 oth | |
| 700 | 1 | |a Tomaras, Stylianos |e investigator |4 oth | |
| 700 | 1 | |a Gromova, Margarita Aleksandrovna |e investigator |4 oth | |
| 700 | 1 | |a Aharonov, Or |e investigator |4 oth | |
| 700 | 1 | |a Hmamouchi, Ihsane |e investigator |4 oth | |
| 700 | 1 | |a Hoff, Leonardo Santos |e investigator |4 oth | |
| 700 | 1 | |a Giannini, Margherita |e investigator |4 oth | |
| 700 | 1 | |a Maurier, François |e investigator |4 oth | |
| 700 | 1 | |a Campagne, Julien |e investigator |4 oth | |
| 700 | 1 | |a Meyer, Alain |e investigator |4 oth | |
| 700 | 1 | |a Nagy-Vincze, Melinda |e investigator |4 oth | |
| 700 | 1 | |a Langguth, Daman |e investigator |4 oth | |
| 700 | 1 | |a Limaye, Vidya |e investigator |4 oth | |
| 700 | 1 | |a Needham, Merrilee |e investigator |4 oth | |
| 700 | 1 | |a Srivastav, Nilesh |e investigator |4 oth | |
| 700 | 1 | |a Hudson, Marie |e investigator |4 oth | |
| 700 | 1 | |a Landon-Cardinal, Océane |e investigator |4 oth | |
| 700 | 1 | |a Shaharir, Syahrul Sazliyana |e investigator |4 oth | |
| 700 | 1 | |a Zuleta, Wilmer Gerardo Rojas |e investigator |4 oth | |
| 700 | 1 | |a Pereira Silva, José António |e investigator |4 oth | |
| 700 | 1 | |a Fonseca, João Eurico |e investigator |4 oth | |
| 700 | 1 | |a Zimba, Olena |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of diabetes investigation |d 2010 |g 15(2024), 1 vom: 01. Jan., Seite 131-138 |w (DE-627)NLM21944952X |x 2040-1124 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g day:01 |g month:01 |g pages:131-138 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jdi.14079 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 1 |b 01 |c 01 |h 131-138 | ||